Memantal pills 10mg, 60pcs

Composition

of film-coated tablets 1 table. Active ingredient:

memantine hydrochloride 10 mg

excipients

core:

lactose monohydrate-149.75 mg; MCC-27.1 mg; talc-11.15 mg; colloidal silicon dioxide-1.25 mg; magnesium stearate-0.75 mg

film shell:

Opadry® white (lactose monohydrate-2.16 mg, hypromellose-1.68 mg, titanium dioxide-1.56 mg, macrogol 4000-0.6 mg) — 6 mg

Pharmacological action

A remedy for the treatment of dementia.

It is a non-competitive antagonist of glutamate NMDA receptors (including in the substantia nigra), as a result, it reduces the excessive stimulating effect of cortical glutamate neurons on the neostriatum, which develops against the background of insufficient dopamine release.

Reducing the supply of Ca2+ to neurons reduces the possibility of their destruction. It has nootropic, cerebrovasodilating, antihypoxic and psychostimulating effects.

  Improves impaired memory, increases the ability to concentrate, reduces fatigue and symptoms of depression, reduces skeletal muscle spasticity caused by diseases or brain damage.

Indications

Moderate to severe dementia in Alzheimer’s disease.

Contraindications

Severe hepatic insufficiency; pregnancy; lactation (breast-feeding); children and adolescents under 18 years of age (efficacy and safety of the drug have not been studied); hypersensitivity to memantine.

Side effects

From the nervous system: dizziness, headache, drowsiness, gait disorders, confusion, hallucinations, convulsions, psychosis, increased excitability.

From the digestive system: constipation, vomiting, nausea, pancreatitis.

From the cardiovascular system: increased blood pressure, venous thrombosis, thromboembolism.

From the body as a whole: fungal infections, general weakness, fatigue, allergic reactions.

Interaction

When used concomitantly, memantine may reduce the effects of barbiturates and antipsychotics. The effect of baclofen and dantrolene may change under the influence of memantine (with this combination, dose adjustment may be required). The effects of levodopa, dopamine receptor agonists, and anticholinergics are enhanced by concomitant use of NMDA receptor antagonists.

Due to the fact that memantine and amantadine are antagonists of NMDA receptors, simultaneous use should be avoided due to the risk of toxic effects. Combinations of memantine with ketamine, dextromethorphan, and phenytoin are also potentially toxic.

For the transport of amantadine, cimetidine, ranitidine, quinidine, quinine and nicotine in the body, the same renal cationic system is used, which can cause the interaction of these drugs with memantine, leading to an increase in its concentration in blood plasma.

When used concomitantly, memantine may cause a decrease in the concentration of hydrochlorothiazide in the blood serum. When used concomitantly with warfarin and other indirect anticoagulants, careful monitoring of prothrombin time and INR is required.

How to take, course of use and dosage

When taken orally, the initial dose for adults is 5 mg / day.

In the future, the dose can be increased weekly by 5 mg.

The average maintenance dose is 10-20 mg / day.

The maximum dose is 20 mg / day.

Special instructions

It should be used with caution in patients with epilepsy, renal insufficiency, thyrotoxicosis, convulsions in the anamnesis, arterial hypertension, a history of myocardial infarction, heart failure. If renal function is impaired, the dose of memantine should be reduced.

With impaired renal function  It is contraindicated in patients with renal insufficiency. If renal function is impaired, the dose of memantine should be reduced.

Form of production

Pills: round, biconvex, film-coated in white, with a wide risk on one side and markings “M9MN” and “10” on the other.

Active ingredient

Memantine

Conditions of release from pharmacies

By prescription

Dosage form

Tablets

Description

For adults as directed by your doctor

Indications

Acquired Dementia, Alzheimer ‘s Disease